HMNC Brain Health to Participate in Upcoming Investor Conferences in April 2022
MUNICH, Germany, April 11, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a global precision psychiatry biopharma company, pioneering the development of personalized therapies powered by its nascent AI platform and predictive companion diagnostics suite, leading to far shorter treatment durations and higher remission rates, announced today that it will present at the following upcoming investor conferences in April 2022.
21st Annual Needham Virtual Healthcare Conference
Date: April 12, 2022
Time: 8:00am ET
Benzinga Psychedelics Capital Conference
Date: April 19, 2022
Time: 1:50pm ET
Date: April 21, 2022
Time: 12:30pm ET
To schedule a one-on-one meeting with HMNC Brain Health’s management team, please contact KCSA Strategic Communications at email@example.com.
About HMNC Brain Health
HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company, pioneering the development of personalized therapies powered by its nascent AI platform and predictive companion diagnostics suite, leading to far shorter treatment durations and higher remission rates. The company develops a unique pipeline for targeting both Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). The company has operations in both the U.S. and Germany and is backed by a renowned global VC, several family offices, and a strategic healthcare investor. HMNC Brain Health now enters the next stage of its development with a large-scale licensing and fundraising agenda.
Alexander Schmidt (Europe)
+49 151 22 99 39 765
Anne Donohoe (U.S.)
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Interim results for the period ended March 31, 202226.5.2022 13:30:47 CEST | Press release
Golar LNG Limited ("Golar" or "the Company") reports Q1 2022 ("Q1") Net income of $345.2 million.Adjusted EBITDA1 of $93.4 million for the quarter inclusive of FLNG Hilli, Golar Arctic and Golar Tundra but excluding the 8 TFDE vessels and management companies sold to Cool Company Ltd. ("CoolCo"). Sold 6.2 million New Fortress Energy Inc. ("NFE") shares in Q2 2022 ("Q2") realizing net cash proceeds of $253 million. Golar now owns 12.4 millionNFE shares following the sale.Q1 Total Golar Cash and Listed Securities1 position increased by $0.4 billion to $1.3 billion. Golar's share of Contractual Debt1 decreased by $0.5 billion to $1.7 billion in Q1 and a further $0.5 billion in Q2 after sale of remaining carriers to CoolCo in April.Agreed to sell the steam turbine carrier Golar Arctic as a converted FSRU to Italy's Snam for 269 million Euros ($288 million). Strong progress made on opportunities for FSRU Golar Tundra and on pipeline of FLNG projects. Shipping spin-off: A key focus for Q1 wa
Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery26.5.2022 13:30:00 CEST | Press release
– Company announces rebranding to Dante Genomics to reflect its broader global efforts – NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company’s pipeline, applying Dante’s internal siRNA and mRNA technology to rare and common diseases. Since the company’s foundation, Dante has invested in a robust R&D program with the goal to create end-to-end solutions from diagnosis to therapy. Dante’s program began with a focus on rare disease, in response to a diagnosis of a patient with a rare disease for which there were no treatment therapies. Dante’s pipeline has evolved across multiple disease areas with four drug programs in full internal development and two in co-development to achieve validation and partner externally on clinical trials and commercialization. “Personalized medicine needs personalized data, a
Tilray Launches CBD Lifestyle Brand, Pollen, on Amazon UK26.5.2022 13:00:00 CEST | Press release
Innovative, Delicious CBD Designed to Make You Feel Your Kind of Good LONDON, May 26, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced the launch of POLLEN, a CBD lifestyle brand with a new approach to wellness, on Amazon UK. Designed to help uncomplicate wellness routines and elevate the CBD experience for consumers, POLLEN offers a unique product mix of tasty CBD gummies and drink drops in three signature lines; ‘Powerbank’ to promote a natural energy boost, ‘No Pressure’ to soften the pressure of everyday stresses and restore your body’s natural bounce, and ‘Soothe You’ for mind and body balance. Each POLLEN product is formulated with CBD and a range of flavorful and vegan-friendly ingredients that simply taste and feel good. Powerbank - Developed to give you that ‘full tan
Sinch resolves on an in-kind issue of shares to the sellers of Pathwire26.5.2022 10:00:00 CEST | Press release
Stockholm, Sweden – 26 May 2022 – Sinch AB (publ) (the “Company” or “Sinch”), a global leader in cloud communications for mobile customer engagement, today announces that the board of directors, in accordance with what was communicated on 7 December 2021, has resolved on an in-kind share issue of 25.5 million shares to the sellers of Pathwire. On 30 September 2021, Sinch disclosed that it had entered into an agreement to acquire Pathwire and the acquisition was completed on 7 December 2021. In addition to the cash consideration, Sinch shall issue an aggregate of 51 million shares in the Company as consideration to the sellers, of which the first 25.5 million shares were issued in February 2022. The board of directors has today resolved to issue the remaining 25.5 million of these shares. The payment of the shares consists of a receivable, under the agreement for the acquisition of Pathwire, against two of the company’s subsidiaries. The contributed receivable amounts to the remaining U
Sinch beslutar om apportemission av aktier till säljarna av Pathwire26.5.2022 10:00:00 CEST | Pressemelding
Stockholm, Sverige – 26 maj 2022 – Sinch AB (publ) (”Bolaget” eller ”Sinch”), en ledande global leverantör av molntjänster för kundinteraktion via mobilen, meddelar idag att styrelsen, i enlighet med vad som har kommunicerats i pressmeddelande den 7 december 2021, har beslutat om apportemission av 25,5 miljoner aktier till säljarna av Pathwire. Sinch offentliggjorde den 30 september 2021 att avtal om att förvärva Pathwire hade ingåtts och förvärvet slutfördes den 7 december 2021. I tillägg till den kontanta köpeskillingen ska Sinch emittera sammanlagt 51 miljoner nya aktier i Sinch som del av vederlaget till säljarna, varav de första 25,5 miljoner aktierna emitterades i februari 2022. Styrelsen har idag beslutat att emittera de resterande 25,5 miljoner aktierna. Betalningen har skett genom apport av en fordran enligt avtalet avseende förvärvet av Pathwire, på två av Bolagets dotterbolag, om de återstående 500 miljoner USD (den initiala delen av fordran om 500 miljoner USD tillfördes i